Roche Holding AG Price to Book Ratio 2012-2025 | RHHBY
Historical price to book ratio values for Roche Holding AG (RHHBY) over the last 10 years. The current price to book ratio for Roche Holding AG as of January 22, 2026 is 8.71.
| Roche Holding AG Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-01-22 | 54.79 | 0.00 | |
| 2024-12-31 | 33.76 | 0.00 | |
| 2024-06-30 | 33.55 | 0.00 | |
| 2023-12-31 | 33.64 | 0.00 | |
| 2023-06-30 | 35.47 | 0.00 | |
| 2022-12-31 | 35.05 | 0.00 | |
| 2022-06-30 | 37.35 | 0.00 | |
| 2021-12-31 | 45.06 | 0.00 | |
| 2021-06-30 | 40.97 | 0.00 | |
| 2020-12-31 | 37.07 | 0.00 | |
| 2020-06-30 | 36.68 | 0.00 | |
| 2019-12-31 | 33.33 | 0.00 | |
| 2019-06-30 | 28.77 | 0.00 | |
| 2018-12-31 | 24.68 | 0.00 | |
| 2018-06-30 | 21.94 | 0.00 | |
| 2017-12-31 | 24.16 | 0.00 | |
| 2017-06-30 | 24.32 | 0.00 | |
| 2016-12-31 | 21.13 | 0.00 | |
| 2016-06-30 | 24.40 | 0.00 | |
| 2015-12-31 | 24.72 | 0.00 | |
| 2015-06-30 | 25.15 | 0.00 | |
| 2014-12-31 | 23.61 | 0.00 | |
| 2014-06-30 | 25.91 | 0.00 | |
| 2013-12-31 | 23.66 | 0.00 | |
| 2013-06-30 | 20.85 | 0.00 | |
| 2012-12-31 | 16.42 | 0.00 | |
| 2012-06-30 | 14.06 | 0.00 | |
| 2011-12-31 | 13.26 | 0.00 | |
| 2011-06-30 | 13.07 | 0.00 | |
| 2010-12-31 | 10.89 | 0.00 | |
| 2010-06-30 | 10.20 | 0.00 | |
| 2009-12-31 | 12.14 | 0.00 | |
| 2009-06-30 | 9.82 | 0.00 | |
| 2008-12-31 | 10.63 | 0.00 | |
| 2008-06-30 | 12.44 | 0.00 | |
| 2007-12-31 | 11.61 | 0.00 | |
| 2007-09-30 | 12.27 | 0.00 | |
| 2007-06-30 | 12.09 | 0.00 | |
| 2006-12-31 | 11.97 | 0.00 | |
| 2006-06-30 | 11.07 | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $349.042B | $68.726B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1027.991B | 49.45 |
| Johnson & Johnson (JNJ) | United States | $526.407B | 20.23 |
| AbbVie (ABBV) | United States | $385.484B | 23.08 |
| Novartis AG (NVS) | Switzerland | $306.301B | 16.24 |
| Novo Nordisk (NVO) | Denmark | $277.857B | 16.29 |
| Merck (MRK) | United States | $270.987B | 12.62 |
| Pfizer (PFE) | United States | $148.397B | 8.16 |
| Sanofi (SNY) | France | $113.414B | 10.97 |
| Bayer (BAYRY) | Germany | $50.732B | 8.90 |
| Innoviva (INVA) | United States | $1.476B | 7.39 |